May 2, 2022
May 2, 2022 –
The U.S. FDA has approved CuvriorTM (trientine tetrahydrochloride) to treat stable Wilson’s disease in adults who are de-coppered and tolerant to penicillamine
May 2, 2022
May 2, 2022 –
The U.S. FDA has approved the first therapeutically equivalent generics for Takeda’s Velcade® (bortezomib). Although Fresenius and Dr. Reddy’s have marketed
April 29, 2022
April 29, 2022 –
The U.S FDA has approved Rinvoq® (upadacitinib – AbbVie) to treat active ankylosing spondylitis (AS) in adults who have an inadequate response or
April 28, 2022
April 28, 2022 –
AstraZeneca’s Ultomiris® (ravulizumab-cwvz) is now approved to treat generalized
myasthenia gravis (gMG) in adults who are anti-acetylcholine
April 28, 2022
May 28, 2022 –
The U.S. FDA has approved Kymriah® (tisagenlecleucel – Novartis) to treat relapsed or refractory follicular lymphoma in adults who have already received
April 28, 2022
April 28 –
VivjoaTM (oteseconazole capsules – Mycovia Pharmaceuticals) has received FDA approval to reduce the incidence of recurrent vulvovaginal candidiasis
April 28, 2022
April 28, 2022 –
Bristol Myers Squibb’s CamzyosTM (mavacamten) has been approved to improve functional capacity and symptoms as a treatment for symptomatic New York
April 25, 2022
April 25, 2022 –
Caplyta® (lumateperone) has received FDA approval for two new dosages strengths: 10.5mg capsules and 21mg capsules.